Myasthenia gravis
Myasthenia gravis results in the weakness of the voluntary skeletal muscle because of inadequate nerve stimulation (Dlugasch & Story , 2021). It is a rare, autoimmune neuromuscular junction disorder. When the motor neuron releases acetylcholine the normal pathophysiology is the binding with nicotinic acetylcholine receptor on the muscle cell membrane to create muscle contraction in MG there is a hypersensitivity which causes cytotoxic injury at the end plate of the neuromuscular junction which inhibits the binding of acetylcholine resulting in lysis or death of the host cells the antibodies from the B-cells inappropriately makes antibodies that bind to nicotinic receptors on the muscle cells arresting the binding or resulted in the inability of the nicotinic receptors to bind with acetylcholine preventing the muscle from contracting.
Treatment for the patient involves pyridostigmine-what does this drug do and how would it benefit our patient?
